LONA
HealthcareLeonaBio, Inc.
$7.69+0.19 (+2.53%)
Prev Close
$7.50
Open
$7.40
High
$7.72
Low
$6.96
Volume
42.8K
Market Cap
$24.3M
P/E
—
Div Yield
—
Over the past 12 months, insider activity at LeonaBio, Inc. (LONA) has been exclusively selling, with 0 insider purchases totaling $0.00 and 20 insider sales totaling $159.0K. The most recent insider transaction was by CHURCH KEVIN (officer: CHIEF SCIENTIFIC OFFICER), who sold $7.3K worth of shares on Mar 5, 2026. LeonaBio, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $24.3M.
Buys (12M)
0
$0.00
Sells (12M)
20
$159.0K
Net Activity
Net Seller
$159.0K
Active Insiders
5
last 12 mo
LONA Price Chart
LONA Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 5, 2026↗ | CHURCH KEVIN | officer: CHIEF SCIENTIFIC OFFICER | Sell | 1,359 | $5.37 | $7.3K | 25,178 |
| Mar 5, 2026↗ | Litton Mark James | director, officer: PRESIDENT and CEO | Sell | 5,156 | $5.37 | $27.7K | 57,926 |
| Mar 5, 2026↗ | Renninger Robert | officer: CHIEF FINANCIAL OFFICER | Sell | 906 | $5.37 | $4.9K | 15,851 |
| Mar 5, 2026↗ | San Martin Javier | officer: CHIEF MEDICAL OFFICER | Sell | 1,720 | $5.37 | $9.2K | 15,887 |
| Mar 5, 2026↗ | Worthington Mark | officer: GENERAL COUNSEL and CCO | Sell | 1,328 | $5.37 | $7.1K | 18,376 |
| Jan 5, 2026↗ | CHURCH KEVIN | officer: CHIEF SCIENTIFIC OFFICER | Sell | 876 | $6.88 | $6.0K | 20,681 |
| Jan 5, 2026↗ | Litton Mark James | director, officer: President and CEO | Sell | 2,586 | $6.88 | $17.8K | 40,828 |
| Jan 5, 2026↗ | Renninger Robert | officer: Chief Financial Officer | Sell | 297 | $6.88 | $2.0K | 12,857 |
| Jan 5, 2026↗ | San Martin Javier | officer: CHIEF MEDICAL OFFICER | Sell | 1,644 | $6.88 | $11.3K | 10,189 |
| Jan 5, 2026↗ | Worthington Mark | officer: General Counsel and CCO | Sell | 876 | $6.88 | $6.0K | 13,978 |
| Dec 31, 2025↗ | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Sell | 876 | $6.88 | $6.0K | 0 |
| Dec 31, 2025↗ | Litton Mark James | President and CEO | Sell | 2,586 | $6.88 | $17.8K | 0 |
| Dec 31, 2025↗ | Renninger Robert | Chief Financial Officer | Sell | 297 | $6.88 | $2.0K | 0 |
| Dec 31, 2025↗ | San Martin Javier | CHIEF MEDICAL OFFICER | Sell | 1,644 | $6.88 | $11.3K | 0 |
| Dec 31, 2025↗ | Worthington Mark | General Counsel and CCO | Sell | 876 | $6.88 | $6.0K | 0 |
| Jun 30, 2025↗ | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Sell | 8,526 | $0.29 | $2.5K | 0 |
| Jun 30, 2025↗ | Litton Mark James | President and CEO | Sell | 25,123 | $0.29 | $7.4K | 0 |
| Jun 30, 2025↗ | Renninger Robert | SVP, Finance and Accounting | Sell | 2,897 | $0.29 | $850.27 | 0 |
| Jun 30, 2025↗ | San Martin Javier | CHIEF MEDICAL OFFICER | Sell | 10,842 | $0.29 | $3.2K | 0 |
| Jun 30, 2025↗ | Worthington Mark | General Counsel and CCO | Sell | 8,526 | $0.29 | $2.5K | 0 |
| Jan 3, 2025↗ | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Sell | 8,510 | $0.56 | $4.8K | 130,761 |
| Jan 3, 2025↗ | Litton Mark James | President and CEO | Sell | 25,107 | $0.56 | $14.1K | 242,591 |
| Jan 3, 2025↗ | Renninger Robert | VP of Finance | Sell | 2,881 | $0.56 | $1.6K | 89,724 |
| Jan 3, 2025↗ | San Martin Javier | CHIEF MEDICAL OFFICER | Sell | 10,826 | $0.56 | $6.1K | 35,841 |
| Jan 3, 2025↗ | Worthington Mark | General Counsel and CCO | Sell | 8,510 | $0.56 | $4.8K | 83,735 |
| Sep 5, 2024↗ | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Sell | 2,525 | $0.57 | $1.4K | 92,684 |
| Sep 5, 2024↗ | Gengos Andrew | CFO and Chief Business Officer | Sell | 1,272 | $0.57 | $719.95 | 97,532 |
| Sep 5, 2024↗ | Lenington Rachel | COO and CDO | Sell | 2,525 | $0.57 | $1.4K | 20,870 |
| Sep 5, 2024↗ | Litton Mark James | President and CEO | Sell | 5,032 | $0.57 | $2.8K | 159,365 |
| Sep 5, 2024↗ | Worthington Mark | GENERAL COUNSEL | Sell | 2,525 | $0.57 | $1.4K | 51,927 |
| Jun 25, 2024↗ | Romano Kelly A | Buy | 42,400 | $2.36 | $100.1K | 80,715 | |
| Jan 8, 2024↗ | CHURCH KEVIN | Chief Scientific Officer | Sell | 2,412 | $2.91 | $7.0K | 80,256 |
| Jan 8, 2024↗ | Gengos Andrew | See Below | Sell | 1,208 | $2.91 | $3.5K | 83,804 |
| Jan 8, 2024↗ | Lenington Rachel | Chief Operating Officer | Sell | 2,412 | $2.91 | $7.0K | 13,395 |
| Jan 8, 2024↗ | Litton Mark James | Chief Executive Officer | Sell | 4,820 | $2.91 | $14.0K | 144,397 |
| Jan 8, 2024↗ | Worthington Mark | General Counsel | Sell | 2,412 | $2.91 | $7.0K | 34,452 |
| Dec 29, 2023↗ | PERCEPTIVE ADVISORS LLC | Director | Buy | 605,686 | $2.42 | $1.46M | 5,402,960 |
| Jun 9, 2023↗ | Gengos Andrew | See Below | Buy | 15,000 | $3.43 | $51.4K | 80,012 |
| Jun 6, 2023↗ | Gengos Andrew | See Below | Buy | 65,012 | $2.95 | $191.6K | 65,012 |
| Mar 31, 2023↗ | PICKERING GRANT | Director | Buy | 25,000 | $2.41 | $60.4K | 25,783 |
| Mar 30, 2023↗ | JOHNSON JAMES A | Director | Buy | 5,000 | $2.40 | $12.0K | 5,000 |
| Dec 30, 2022↗ | MILESON GLENNA | Chief Financial Officer | Buy | 50,000 | $2.85 | $142.3K | 159,930 |
| Dec 6, 2022↗ | Romano Kelly A | Director | Buy | 30,000 | $3.29 | $98.7K | 38,315 |
| Nov 17, 2022↗ | MOEBIUS HANS | Chief Medical Officer | Buy | 5,000 | $3.29 | $16.4K | 65,836 |
| Jul 1, 2022↗ | PERCEPTIVE ADVISORS LLC | Director | Buy | 1,371,362 | $2.99 | $4.10M | 4,797,280 |
| Jun 30, 2022↗ | MOEBIUS HANS | Chief Medical Officer | Buy | 10,000 | $2.88 | $28.8K | 52,955 |
| Jun 24, 2022↗ | CHURCH KEVIN | Executive VP, Research | Sell | 2,614 | $2.69 | $7.0K | 57,695 |
| Jun 24, 2022↗ | Lenington Rachel | Chief Operating Officer | Sell | 4,193 | $2.69 | $11.3K | 5,807 |
| Jun 24, 2022↗ | Litton Mark James | Chief Executive Officer | Sell | 7,960 | $2.69 | $21.4K | 128,555 |
| Jun 24, 2022↗ | MILESON GLENNA | Chief Financial Officer | Sell | 2,614 | $2.69 | $7.0K | 109,167 |
| Jun 24, 2022↗ | Worthington Mark | General Counsel | Sell | 2,614 | $2.69 | $7.0K | 19,097 |
| Apr 1, 2022↗ | Romano Kelly A | Director | Buy | 8,000 | $13.11 | $104.9K | 8,315 |
LONA Insider Buying Activity
The following table shows recent insider purchases of LeonaBio, Inc. (LONA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 25, 2024↗ | Romano Kelly A | Buy | 42,400 | $2.36 | $100.1K | 80,715 | |
| Dec 29, 2023↗ | PERCEPTIVE ADVISORS LLC | Director | Buy | 605,686 | $2.42 | $1.46M | 5,402,960 |
| Jun 9, 2023↗ | Gengos Andrew | See Below | Buy | 15,000 | $3.43 | $51.4K | 80,012 |
| Jun 6, 2023↗ | Gengos Andrew | See Below | Buy | 65,012 | $2.95 | $191.6K | 65,012 |
| Mar 31, 2023↗ | PICKERING GRANT | Director | Buy | 25,000 | $2.41 | $60.4K | 25,783 |
| Mar 30, 2023↗ | JOHNSON JAMES A | Director | Buy | 5,000 | $2.40 | $12.0K | 5,000 |
| Dec 30, 2022↗ | MILESON GLENNA | Chief Financial Officer | Buy | 50,000 | $2.85 | $142.3K | 159,930 |
| Dec 6, 2022↗ | Romano Kelly A | Director | Buy | 30,000 | $3.29 | $98.7K | 38,315 |
| Nov 17, 2022↗ | MOEBIUS HANS | Chief Medical Officer | Buy | 5,000 | $3.29 | $16.4K | 65,836 |
| Jul 1, 2022↗ | PERCEPTIVE ADVISORS LLC | Director | Buy | 1,371,362 | $2.99 | $4.10M | 4,797,280 |
| Jun 30, 2022↗ | MOEBIUS HANS | Chief Medical Officer | Buy | 10,000 | $2.88 | $28.8K | 52,955 |
| Apr 1, 2022↗ | Romano Kelly A | Director | Buy | 8,000 | $13.11 | $104.9K | 8,315 |
LONA Insider Selling Activity
The following table shows recent insider sales of LeonaBio, Inc. (LONA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 5, 2026↗ | CHURCH KEVIN | officer: CHIEF SCIENTIFIC OFFICER | Sell | 1,359 | $5.37 | $7.3K | 25,178 |
| Mar 5, 2026↗ | Litton Mark James | director, officer: PRESIDENT and CEO | Sell | 5,156 | $5.37 | $27.7K | 57,926 |
| Mar 5, 2026↗ | Renninger Robert | officer: CHIEF FINANCIAL OFFICER | Sell | 906 | $5.37 | $4.9K | 15,851 |
| Mar 5, 2026↗ | San Martin Javier | officer: CHIEF MEDICAL OFFICER | Sell | 1,720 | $5.37 | $9.2K | 15,887 |
| Mar 5, 2026↗ | Worthington Mark | officer: GENERAL COUNSEL and CCO | Sell | 1,328 | $5.37 | $7.1K | 18,376 |
| Jan 5, 2026↗ | CHURCH KEVIN | officer: CHIEF SCIENTIFIC OFFICER | Sell | 876 | $6.88 | $6.0K | 20,681 |
| Jan 5, 2026↗ | Litton Mark James | director, officer: President and CEO | Sell | 2,586 | $6.88 | $17.8K | 40,828 |
| Jan 5, 2026↗ | Renninger Robert | officer: Chief Financial Officer | Sell | 297 | $6.88 | $2.0K | 12,857 |
| Jan 5, 2026↗ | San Martin Javier | officer: CHIEF MEDICAL OFFICER | Sell | 1,644 | $6.88 | $11.3K | 10,189 |
| Jan 5, 2026↗ | Worthington Mark | officer: General Counsel and CCO | Sell | 876 | $6.88 | $6.0K | 13,978 |
| Dec 31, 2025↗ | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Sell | 876 | $6.88 | $6.0K | 0 |
| Dec 31, 2025↗ | Litton Mark James | President and CEO | Sell | 2,586 | $6.88 | $17.8K | 0 |
| Dec 31, 2025↗ | Renninger Robert | Chief Financial Officer | Sell | 297 | $6.88 | $2.0K | 0 |
| Dec 31, 2025↗ | San Martin Javier | CHIEF MEDICAL OFFICER | Sell | 1,644 | $6.88 | $11.3K | 0 |
| Dec 31, 2025↗ | Worthington Mark | General Counsel and CCO | Sell | 876 | $6.88 | $6.0K | 0 |
| Jun 30, 2025↗ | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Sell | 8,526 | $0.29 | $2.5K | 0 |
| Jun 30, 2025↗ | Litton Mark James | President and CEO | Sell | 25,123 | $0.29 | $7.4K | 0 |
| Jun 30, 2025↗ | Renninger Robert | SVP, Finance and Accounting | Sell | 2,897 | $0.29 | $850.27 | 0 |
| Jun 30, 2025↗ | San Martin Javier | CHIEF MEDICAL OFFICER | Sell | 10,842 | $0.29 | $3.2K | 0 |
| Jun 30, 2025↗ | Worthington Mark | General Counsel and CCO | Sell | 8,526 | $0.29 | $2.5K | 0 |
| Jan 3, 2025↗ | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Sell | 8,510 | $0.56 | $4.8K | 130,761 |
| Jan 3, 2025↗ | Litton Mark James | President and CEO | Sell | 25,107 | $0.56 | $14.1K | 242,591 |
| Jan 3, 2025↗ | Renninger Robert | VP of Finance | Sell | 2,881 | $0.56 | $1.6K | 89,724 |
| Jan 3, 2025↗ | San Martin Javier | CHIEF MEDICAL OFFICER | Sell | 10,826 | $0.56 | $6.1K | 35,841 |
| Jan 3, 2025↗ | Worthington Mark | General Counsel and CCO | Sell | 8,510 | $0.56 | $4.8K | 83,735 |
| Sep 5, 2024↗ | CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Sell | 2,525 | $0.57 | $1.4K | 92,684 |
| Sep 5, 2024↗ | Gengos Andrew | CFO and Chief Business Officer | Sell | 1,272 | $0.57 | $719.95 | 97,532 |
| Sep 5, 2024↗ | Lenington Rachel | COO and CDO | Sell | 2,525 | $0.57 | $1.4K | 20,870 |
| Sep 5, 2024↗ | Litton Mark James | President and CEO | Sell | 5,032 | $0.57 | $2.8K | 159,365 |
| Sep 5, 2024↗ | Worthington Mark | GENERAL COUNSEL | Sell | 2,525 | $0.57 | $1.4K | 51,927 |
| Jan 8, 2024↗ | CHURCH KEVIN | Chief Scientific Officer | Sell | 2,412 | $2.91 | $7.0K | 80,256 |
| Jan 8, 2024↗ | Gengos Andrew | See Below | Sell | 1,208 | $2.91 | $3.5K | 83,804 |
| Jan 8, 2024↗ | Lenington Rachel | Chief Operating Officer | Sell | 2,412 | $2.91 | $7.0K | 13,395 |
| Jan 8, 2024↗ | Litton Mark James | Chief Executive Officer | Sell | 4,820 | $2.91 | $14.0K | 144,397 |
| Jan 8, 2024↗ | Worthington Mark | General Counsel | Sell | 2,412 | $2.91 | $7.0K | 34,452 |
| Jun 24, 2022↗ | CHURCH KEVIN | Executive VP, Research | Sell | 2,614 | $2.69 | $7.0K | 57,695 |
| Jun 24, 2022↗ | Lenington Rachel | Chief Operating Officer | Sell | 4,193 | $2.69 | $11.3K | 5,807 |
| Jun 24, 2022↗ | Litton Mark James | Chief Executive Officer | Sell | 7,960 | $2.69 | $21.4K | 128,555 |
| Jun 24, 2022↗ | MILESON GLENNA | Chief Financial Officer | Sell | 2,614 | $2.69 | $7.0K | 109,167 |
| Jun 24, 2022↗ | Worthington Mark | General Counsel | Sell | 2,614 | $2.69 | $7.0K | 19,097 |
LONA Insiders
Similar Stocks to LONA
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$536.12+0.97%
$23.50B
MRNA
Moderna, Inc.
$52.56-1.89%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.06-1.44%
$20.08B
RPRX
Royalty Pharma plc
$45.65-0.57%
$19.56B